20/20 Biolabs
AIDX0.44133.22% ( -0.0147 )
20/20 Biolabs (AIDX)
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases....
- Open
- 0.4599
- High
- 0.4599
- Low
- 0.4304
- Prev. Close
- 0.4560
- Volume
- 70.68K
- Turnover
- 31.61K
- Avg Price
- 0.4473
- Bid/Ask Ratio
- --
- Amplitude
- 6.47%
- 52wk High
- 50.0000
- Volume Ratio
- 0.51
- Turnover Ratio
- 1.31%
20/20 Biolabs Analyst Rating
View MoreForecast & Rating
May 21, 2026Price forecast
$5.001033.02%
Forecast & RatingBuy
1analysts
- Strong buy0.00%
- Buy100.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Unusual Whales · Jul 30 at 07:34 AM
20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management’s Recent East Asia Business Development Tour
- PUBT · Jul 30 at 07:33 AM
20/20 BioLabs to host investor webinar on East Asia business development tour
- StockTitan · Jul 27 at 07:30 AM
20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy | AIDX Stock News
- StockTitan · Jul 22 at 11:31 PM
20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock | AIDX Stock News
- TradingView · Jul 1 at 02:33 PM
20/20 Biolabs to present OneTest webinar outlining Medicare pathway, modeling and reimbursement plan
- StockTitan · Jun 22 at 07:45 AM
20/20 BioLabs Announces Monthly Investor Webinar Series to be Held on the First Wednesday of Each Month | AIDX Stock News
